2022
DOI: 10.2298/vsp201207028j
|View full text |Cite
|
Sign up to set email alerts
|

The role of c-MYC expression in the diagnostic and clinical confirmation of radiation-induced angiosarcoma

Abstract: Introduction. Angiosarcomas (AS) arising from vascular tissue, accounting for 3.3% of all sarcomas, have a poor prognosis. Radiation-induced AS is a rare late complication of radiotherapy treatment and is characterized by a gene expression profile such as amplification of the MYC oncogene, by which we can distinguish primary from the secondary induced tumor. Case report, At 77-year-old patient, with early-stage endometrial adenocarcinoma, the radical hysterectomy with bilateral salpingo-oopho… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 29 publications
0
2
0
Order By: Relevance
“…According to these criteria, RIM must appear within treated volumes with a sufficiently long latent period and must have a different histology compared to primary malignancy, and the tissue origin of the RIM must be free of diagnosed metabolic and genetic malformations prior to radiation. (41) After multidisciplinary treatment of Hodgkin lymphoma, patients are most often at risk of developing leukemia (e.g., acute myeloblastic leukemia) as well as solid tumors (most often cancers of the thyroid gland, breast, and bone sarcomas). Leukemia, which occurs in the first 4 to 10 years after treatment, is primarily associated with alkylating agents as part of chemotherapy protocols (42).…”
Section: Acute and Late Toxicity Of Radiation Therapymentioning
confidence: 99%
“…According to these criteria, RIM must appear within treated volumes with a sufficiently long latent period and must have a different histology compared to primary malignancy, and the tissue origin of the RIM must be free of diagnosed metabolic and genetic malformations prior to radiation. (41) After multidisciplinary treatment of Hodgkin lymphoma, patients are most often at risk of developing leukemia (e.g., acute myeloblastic leukemia) as well as solid tumors (most often cancers of the thyroid gland, breast, and bone sarcomas). Leukemia, which occurs in the first 4 to 10 years after treatment, is primarily associated with alkylating agents as part of chemotherapy protocols (42).…”
Section: Acute and Late Toxicity Of Radiation Therapymentioning
confidence: 99%
“…These tumors appear within the limits of the radiation volume after a latent period of more than four years. Also, the histopathological type of the tumor differs from the type of the primary tumor (44).…”
Section: Adverse Effects Of R Adiother Apymentioning
confidence: 99%